Breaking news on Diagnostics business, policy & funding.
With the certification, the Silicon Valley-based company aims to roll out its AvaGen test for keratoconus and corneal dystrophies beginning this quarter.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
The investment banks cited the company's access to proprietary technology and the potential $5 billion market for Exagen's testing options as reasons for its Outperform rating.
The companies will develop an assay to guide treatment with a type of radiopharmaceutical therapy in patients with these rare tumors.
The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.